Pillay Thasee, Neves Paulo, Benetti Federico, Van Bladel Kevin, Wechsler Andrew, Annest Lon
BioVentrix Inc., San Ramon, California, USA.
Department of Cardiothoracic Surgery, Centro Hospitalar de Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.
J Card Surg. 2021 Jan;36(1):300-306. doi: 10.1111/jocs.15117. Epub 2020 Nov 1.
The Revivent TC™ Transcatheter Ventricular Enhancement System (BioVentrix Inc.) is intended for use in heart failure with cardiac dysfunction a previous myocardial infarction. The resultant increased left ventricular systolic volume and discrete, contiguous, noncontractile (akinetic and/or dyskinetic) scar located in the anteroseptal, apical (may extend laterally) region of the left ventricle (LV) lends itself to Revivent. The procedure, called Less Invasive Ventricular Enhancement, consists of the implantation of a series of microanchors pairs to exclude the scarred myocardium, to reduce and reshape the LV. We present the procedure step-by-step, as team coordination between the cardiac surgeon and the interventional cardiologist is essential to ensure good procedural outcomes. This is a novel and new technique to address heart failure secondary to myocardial infarction.
Revivent TC™经导管心室增强系统（BioVentrix公司）旨在用于患有心脏功能障碍且既往有心肌梗死的心力衰竭患者。由此导致的左心室收缩容积增加以及位于左心室（LV）前间隔、心尖（可能延伸至外侧）区域的离散、连续、无收缩功能（运动减弱和/或运动障碍）瘢痕适合使用Revivent系统。该手术称为微创心室增强术，包括植入一系列微型锚定器对，以排除瘢痕化心肌，缩小并重塑左心室。我们将逐步介绍该手术，因为心脏外科医生和介入心脏病专家之间的团队协作对于确保良好的手术效果至关重要。这是一种治疗心肌梗死后继发性心力衰竭的新颖技术。
